Amgen risk signals are already mainstreamed - keep the short thesis, drop the urgency
The Opportunity
The directional call remains SHORT upstream: negative mechanism sign tied to a compliance/regulatory framing. The economic logic for the short is straightforward - compliance overhangs typically mean higher legal spend, management distraction, and risk-premium widening when the market is forced to quantify unknowns.
The Timing
This is INVESTIGATE because the lifecycle is spreading/decaying edge. To turn this back into a TRADE-quality window you would need a new, non-consensus hook (a fresh filing, a regulator artefact, or a sharply framed incremental allegation) rather than recycled commentary. In a Mixed 68 tape with high crosswinds, late-cycle regulatory narratives are more likely to be churned than repriced.
The Evidence
Upstream explicitly notes Tier-1 domain presence for this cluster, which is the core reason it is in propagation_monitor. Freshness and hydrated evidence links are not provided here. Treat it as a reminder to stress-test existing AMGN exposure rather than as a primary-source-driven new short entry.